-
Mashup Score: 3Post-Treatment Mortality After Surgery and Stereotactic Body Radiotherapy for Early-Stage Non-Small-Cell Lung Cancer - PubMed - 2 day(s) ago
Purpose In early-stage non-small cell lung cancer (NSCLC), post-treatment mortality may influence the comparative effectiveness of surgery and stereotactic body radiotherapy (SBRT), with implications for shared decision making among high-risk surgical candidates. We analyzed early mortality after th …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 6Post-Treatment Mortality After Surgery and Stereotactic Body Radiotherapy for Early-Stage Non–Small-Cell Lung Cancer - 3 day(s) ago
Purpose In early-stage non–small cell lung cancer (NSCLC), post-treatment mortality may influence the comparative effectiveness of surgery and stereotactic body radiotherapy (SBRT), with implications for shared decision making among high-risk surgical candidates. We analyzed early mortality after these interventions using the National Cancer Database. Patients and Methods We abstracted patients with cT1-T2a, N0, M0 NSCLC diagnosed between 2004 and 2013 undergoing either surgery or SBRT. Thirty-day and 90-day post-treatment mortality rates were calculated and compared using Cox regression and propensity score–matched analyses. Results We identified 76,623 patients who underwent surgery (78% lobectomy, 20% sublobar resection, 2% pneumonectomy) and 8,216 patients who received SBRT. In the unmatched cohort, mortality rates were moderately increased with surgery versus SBRT (30 days, 2.07% v 0.73% [absolute difference (Δ), 1.34%]; P < .001; 90 days, 3.59% v 2.93% [Δ, 0.66%]; P < .001). Amon
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Prognostic factors affecting the risk of thoracic progression in extensive-stage small cell lung cancer - 24 day(s) ago
The efficacy of combined modality therapy is evaluated for patients with extensive-stage (ES) small cell lung cancer (SCLC). This study evaluated prognostic factors affecting the risk of thoracic progression in ES-SCLC patients likely to undergo thoracic …
Source: www.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0
Abstract. Radiotherapy may induce off-target antitumor “abscopal” immunostimulatory but also immunosuppressive effects. Several preclinical and early clini
Source: academic.oup.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 7Treatment Decision Drivers in Stage III Non–Small-Cell Lung Cancer: Outcomes of a Web-Based Survey of Oncologists in the United States - 1 month(s) ago
PURPOSE: We conducted a cross-sectional survey of practicing medical oncologists in the United States to obtain insight into physician and patient treatment decision making in stage III non–small-cell lung cancer (NSCLC). METHODS: A convenience sample of 150 oncologists completed a 38-question Web-based survey in January 2019. RESULTS: Surveyed oncologists (82% community based) had an average of 15 years of clinical experience and had treated an average of 20 patients newly diagnosed with stage III NSCLC in the previous 6 months. Oncologists reported presenting 55% of their patients with stage III NSCLC to tumor boards. For patients with new unresectable stage III NSCLC seen in the previous 6 months, concurrent chemoradiation therapy (cCRT) was reported as the initial treatment in an average of 48% of patients. The most frequent reason for delays in starting the initial chosen treatment was insurance preauthorization processes (reported by 65% of oncologists). A total of 55% of all pat
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 43
At the Forefront of Cardiothoracic Surgery, AATS members have a proven record of distinction within the specialty and have made significant contributions to the care and treatment of cardiothoracic disease.
Source: www.aats.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 38th Zurich Immuno-Oncology Symposium - 2 month(s) ago
The 8th Zurich Immuno-Oncology Symposium will bring together clinicians and scientists from across the field of cancer immunotherapy to deepen the understanding of cancer, the immune system and immunotherapy.
Source: www.usz.chCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 38th Zurich Immuno-Oncology Symposium - 2 month(s) ago
The 8th Zurich Immuno-Oncology Symposium will bring together clinicians and scientists from across the field of cancer immunotherapy to deepen the understanding of cancer, the immune system and immunotherapy.
Source: www.usz.chCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 36
At the Forefront of Cardiothoracic Surgery, AATS members have a proven record of distinction within the specialty and have made significant contributions to the care and treatment of cardiothoracic disease.
Source: www.aats.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 38th Zurich Immuno-Oncology Symposium - 3 month(s) ago
The 8th Zurich Immuno-Oncology Symposium will bring together clinicians and scientists from across the field of cancer immunotherapy to deepen the understanding of cancer, the immune system and immunotherapy.
Source: www.usz.chCategories: General Medicine News, Hem/OncsTweet
@DrewMoghanaki @huroqu90 @MKamelHusseinMD @nchudgar @EinsteinMed @AATSHQ @AATSJournals But we modeled it on a previous paper from @JCO_ASCO using the same NCDB. This one agreed w/ your preconceived notions. I don’t remember you attacking the methodology on that one. You may have even promoted it. Please remind me… 🙏 https://t.co/qsI0tsdt5l